We report that human secretory breast carcinoma (SBC), a rare subtype of infiltrating ductal carcinoma, expresses the ETV6-NTRK3 gene fusion previously cloned in pediatric mesenchymal cancers. This gene fusion encodes a chimeric tyrosine kinase with potent transforming activity in fibroblasts. ETV6-NTRK3 expression was confirmed in 12 (92%) of 13 SBC cases, but not in other ductal carcinomas. Retroviral transfer of ETV6-NTRK3 (EN) into murine mammary epithelial cells resulted in transformed cells that readily formed tumors in nude mice. Phenotypically, tumors produced glands and expressed epithelial antigens, confirming that EN transformation is compatible with epithelial differentiation. This represents a recurrent chromosomal rearrangement and expression of a dominantly acting oncogene as a primary event in human breast carcinoma.
Introduction
t(12;15)(p13;q25) associated with congenital fibrosarcoma (CFS), a pediatric spindle cell malignancy of the soft tissues Among human solid tumors, sporadic breast cancer is similar (Knezevich et al., 1998b) . This rearrangement generates a gene to the vast majority of epithelial malignancies in that it appears to fusion encoding the sterile ␣ motif (SAM) dimerization domain of have a complex genetic etiology. The numerous rearrangements the ETV6 (TEL) transcription factor linked to the protein tyrosine and gains and losses of chromosomal material observed cytokinase (PTK) domain of the neurotrophin-3 receptor NTRK3 gentically in tumor cells have precluded the discovery of primary (TRKC) (Knezevich et al., 1998b) . The resulting ETV6-NTRK3 genetic lesions underlying breast cancer development (Dickson (EN) protein functions as a chimeric PTK with potent transand Lippman, 2001) . This is in contrast to bone and soft tissue forming activity (Wai et al., 2000; Liu et al., 2000) . EN expression sarcomas of children and young adults, which often show recurleads to constitutive activation of two major effector pathways rent chromosomal translocations leading to expression of gene of wild-type NTRK3, namely the Ras-MAP kinase (MAPK) mitofusions thought to be causally related to oncogenesis (Ladanyi genic pathway and the phosphatidyl inositol-3-kinase (PI3K) and Bridge, 2000) . However, the occurrence of such transloca-AKT pathway mediating cell survival, and both are required for tions as the sole cytogenetic alteration in epithelial tumors is EN transformation (Wai et al., 2000; Tognon et al., 2001 ). ETV6-extremely rare.
NTRK3 fusion transcripts have also been identified in a related pediatric tumor, cellular mesoblastic nephroma (CMN) (KnezeWe previously cloned the translocation breakpoints of the
S I G N I F I C A N C E
Mechanisms of oncogenesis in sporadic breast cancer remain for the most part obscure. This is due in large part to the marked cytogenetic complexity seen in most breast cancers, precluding investigators from readily identifying primary genetic events that may be causative in breast cell transformation. Our findings, although limited to a rare but distinct subset of breast cancers, describe a potentially causative genetic event in sporadic human breast carcinoma and establish ETV6-NTRK3 as a dominantly acting oncogene in this disease. Therefore, the transformation of breast epithelial cells by the ETV6-NTRK3 oncoprotein may provide an extremely useful model to study pathways underlying the initiation and progression of human breast cancer, and how those pathways may be targeted therapeutically. A: Histology of index secretory breast carcinoma (SBC) case demonstrating well-differentiated but invasive glands containing eosinophilic secretions. B: Partial karyogram demonstrating the t(12;15)(p13;q25) in secretory breast carcinoma occurring in a 6-year-old female. Arrowheads show breakpoints at derivative 12p13 and derivative 15q25. C: Dual color FISH using ETV6 exon 1-containing cosmid 179A6 (green) and ETV6 exon 8-containing cosmid 148B6 (Knezevich et al., 1998b) . Arrows show separate signals indicating disruption of the ETV6 gene. vich et al., 1998a; Rubin et al., 1998) , and in a case report an infiltrating pattern of neoplastic epithelial cells forming wellof adult acute myeloid leukemia (AML) (Eguchi et al., 1999) . differentiated glandular lumens filled with eosinophilic PAS-posTherefore, this gene fusion is unique in being expressed in both itive secretions (Rosen and Cranor, 1991) . Karyotypic analysis mesenchymal and hematopoietic lineages. revealed a t(12;15)(p12;q26.1) translocation as the only cytogeThe possibility that ETV6-NTRK3 fusion transcripts are exnetic abnormality in tumor cells ( Figure 1B ). This translocation pressed in human breast cancer was suggested to us by cytogewas not present constitutionally. The karyotype prompted us netic analysis of an invasive breast adenocarcinoma diagnosed to perform fluorescence in situ hybridization (FISH) and reverse in a 6-year-old female. This revealed a nonconstitutional transcriptase PCR (RT-PCR) on frozen tumor tissue from the t(12;15)(p12;q26.1) as the only karyotypic abnormality in tumor case to screen for the ETV6-NTRK3 gene fusion. As shown in cells. The histopathologic features of the tumor were those of Figure 1C , dual color FISH using cosmid probes from exon 1 a secretory breast carcinoma (SBC). This is a rare but distinct and exon 8 of ETV6 demonstrated rearrangement of the ETV6 subtype of infiltrating ductal carcinoma (IDC) that was originally locus. Moreover, RT-PCR revealed an identical 731 bp fusion described in children and adolescents, but is now known to transcript as previously described for CFS and CMN (Knezevich occur with equal incidence in adults (Page et al., 1987; Oberman, et al., 1998a Oberman, et al., , 1998b (Figure 2A ). This was confirmed by se-1980). Although recurrences and nodal metastases can occur quencing of the amplification products, which demonstrated in SBC, the prognosis was initially thought to be excellent comthe identical fusion point between ETV6 nucleotide 1033 and pared to typical IDC, with up to a 100% five-year survival rate NTRK3 nucleotide 1601 as previously shown for sarcoma-asso- (Tavassoli and Norris, 1980; Rosen and Cranor, 1991) . However, ciated fusions (Knezevich et al., 1998b ) ( Figure 2B ). This differs more recent studies have suggested that the favorable outcome from the ETV6-NTRK3 gene fusion reported in a case of acute is age-related, and that in older patients the prognosis is similar myeloid leukemia, in which ETV6 exon 5 was not present in the to IDC (Maitra et al., 1999) . In this report we demonstrate that fusion (Eguchi et al., 1999) . Furthermore, we generated RT-PCR SBC is characterized by expression of the ETV6-NTRK3 gene products from the SBC case using the TEL 114 primer (located fusion, and that ETV6-NTRK3 can transform mammary epithelial 5Ј of the ETV6 SAM sequence) in combination with the TRKC2 cells. This fusion oncoprotein is therefore causally related to primer located within the NTRK3 PTK sequence (Knezevich et transformation across all germ layers, a finding which has potenal., 1998b), as well as using the TEL 541 primer from ETV6 exon tial implications for how we view the specificity of chromosomal 5 (Knezevich et al., 1998b) in conjunction with the Trk1 primer translocations in human tumors. (Wai et al., 2000) from exon 18 of NTRK3 located 3Ј of the PTK sequence (Ichaso et al., 1998 ) (see Figure 2B ). These products Results were confirmed to contain identical sequences to those of CFS fusion transcripts and demonstrated that the entire SAM and Identification of the t(12;15) translocation and ETV6-NTRK3 PTK domains were included in the SBC transcripts (see Gengene fusion in a human secretory breast carcinoma case Bank accession #AF041811). We also found that, similar to CFS The index case was a 6-year-old female who presented with a gene fusions, SBC transcripts did not contain NTRK3 exon 16, unilateral breast mass. Pathology revealed an invasive breast which encodes a 42 bp insert within the PTK sequences (Ichaso adenocarcinoma with the histopathologic features of a secretory breast carcinoma (SBC) ( Figure 1A ). SBC is characterized by et al., 1998). The presence of these naturally occurring inserts . An expanded view of the ETV6-NTRK3 breakpoint sequence in the index secretory breast carcinoma case is shown below the cDNA schematic. This was derived by sequencing of RT-PCR products using primers TEL-541 and TRKC2. Identical sequences were observed in multiple clones from three separate experiments. The vertical arrow shows the fusion point. C: Immunoprecipitation of the ETV6-NTRK3 protein using ␣-NTRK3 antibodies followed by Western analysis with ␣-phosphotyrosine antibodies. The left panel demonstrates the characteristic tyrosine phosphorylated 68/73 kDa ETV6-NTRK3 doublet in the index secretory breast carcinoma case (SBC), two CFS primary tumors (CFS1 and 2), and in NIH3T3 cells expressing ETV6-NTRK3 (3T3-EN), but not in the NIH3T3 vector control (3T3-Vec). The right panel demonstrates the doublet only in the 3T3-EN control cells but not in lysates from three invasive breast carcinoma cases (IBC1-3) nor in 3T3-Vec cells. The 68/73 kDa ETV6-NTRK3 doublet is indicated by the arrow.
is known to decrease NTRK3 PTK activity (reviewed in Barbacid, fully cloned PCR products from four of these additional positive cases, and sequence analysis confirmed that all four had 1994).
breakpoint sequences that were identical to each other and to To show that the ETV6-NTRK3 protein was expressed in a control CFS case, with fusion points between ETV6 nucleotide tumor tissue, we performed immunoprecipitation of whole cell 1033 and NTRK3 nucleotide 1601 (data not shown). To test lysates from the primary tumor using ␣-NTRK3 antibodies folwhether this gene fusion is specific for SBC, we also screened lowed by Western blotting with ␣-phosphotyrosine antibodies a series of banked frozen specimens from 50 cases of typical as described (Wai et al., 2000) . This revealed expression of the IDC as well as FFPE blocks from 5 of these cases (cases 14-18 characteristic tyrosine phosphorylated 68/73 kDa doublet of EN of Table 1 ). All were fusion negative except for one case (case ( Figure 2C , left panel), which was confirmed by reprobing of the 14 of Table 1 ), in which, unexpectedly, fusion transcripts could blot with ␣-NTRK3 and ␣-ETV6 antibodies (data not shown).
be demonstrated in both the frozen specimen and in the correThe tyrosine phosphorylated doublet was not detected in three sponding FFPE block from this case ( Figure 3A ). control primary invasive ductal carcinomas that were negative
To confirm these findings, we next performed dual color for the ETV6-NTRK3 gene fusion by RT-PCR ( Figure 2C , right FISH analysis on nuclei isolated from FFPE blocks using yeast panel).
artificial chromosomes (YACs) containing the ETV6 and NTRK3 loci, respectively. Nine of the 13 SBC cases (including the index Analysis of ETV6-NTRK3 transcript expression case) had adequately preserved nuclei for FISH analysis, as did in a series of secretory breast carcinomas each of the five IDC FFBE blocks. The nine SBC cases with To test whether ETV6-NTRK3 expression represents a generalevaluable nuclei were all positive by FISH for the ETV6-NTRK3 ized finding in SBC, we accrued 12 additional breast cancer gene fusion (see Figure 3B and Table 1 ). Moreover, the IDC cases in which SBC was the predominant or only histologic case that was positive by RT-PCR (case 13) was also positive component (for clinical features see Table 1 ). The diagnoses by FISH while the other FFBE blocks were negative (Table 1) . were independently confirmed by three of the authors (DH, CP, Further review of pathologic material from case 14 revealed and PHBS). Only formalin-fixed paraffin-embedded (FFPE) tuseveral areas of well-differentiated glands containing eosinomor blocks were available for each case. We therefore used an philic secretions (data not shown). Therefore this case may have RT-PCR assay adapted to FFPE tissue which detects a 110 bp originated as an SBC, but underwent further clonal evolution to fragment (Bourgeois et al., 2000) . We detected ETV6-NTRK3 assume a less differentiated phenotype. These findings strongly fusion transcripts in 11 of the 12 cases, as well as in FFPE indicate that the ETV6-NTRK3 gene fusion is a nonrandom rearrangement in SBC. blocks from the index case ( Figure 3A and Table 1 ). We success- 
ETV6-NTRK3 transforms Eph4 and Scg6 breast and Scg6 cells. These are immortalized nontransformed epitheepithelial cells
lial cell lines derived from normal mouse mammary epithelium To demonstrate that ETV6-NTRK3 has transformation activity (Roskelley et al., 2000; Somasiri et al., 2001 ). We chose these in breast epithelial cells, we used previously described retroviral lines because they represent opposite ends of the spectrum gene transfer methods (Wai et al., 2000) to express EN conof mammary epithelial differentiation, with Scg6 cells showing structs versus vector alone in clonal populations of murine Eph4 stable myoepithelial (more mesenchymal) features and Eph4 cells showing a stable epithelial phenotype in culture. After infection with ETV6-NTRK3 constructs, both cell lines were found to express ETV6-NTRK3 at levels that were equivalent to those observed in EN-transformed NIH3T3 cells ( Figure 4A ). Morphology of Eph4-EN and Scg6-EN cells in monolayer cultures suggested a transformed phenotype compared with vector alone cells (data not shown). To more rigorously demonstrate that EN had transforming ability in these cells, EN-expressing and vector alone cells were simultaneously injected subcutaneously into the right or left flanks, respectively, of nude mice. Tumor formation was then monitored for up to six weeks in comparison with EN-expressing NIH3T3 cells. Eph4 and Scg6 cells containing vector alone showed no tumor formation whatsoever ( Figure  4B ). In contrast, both cell lines formed obvious tumors when engineered to express EN. All Eph4-EN and Scg6-EN injection sites showed tumor formation, although tumor sizes were variable ( Figure 4B ). Interestingly, tumors derived from the two breast epithelial cell lines consistently grew more slowly compared with EN-expressing NIH3T3 cells, although they eventually attained the same sizes and weights ( Figure 4C ). These findings confirm that EN has transformation activity in breast A: Reverse transcriptase-PCR of ETV6-NTRK3 fusion transcripts (arrow) using total RNA isolated from formalin-fixed paraffin-embedded tumor blocks of
Pathology of tumors derived from ETV6-NTRK3
the index secretory breast carcinoma case (SBC) as well as in cases 2, 3, and 14 from (Knezevich et al., 1998b) . Representative fusion signals are shown by the arrows.
sarcoma appearance of EN-expressing NIH3T3 tumors (see Fig-Figure 4 . ures 5A and 5B). There was no gland formation or other evidence tumor cells maintained the ability to undergo epithelial differentiation, which is consistent with our premise that EN is a transof epithelial differentiation. As shown in Figures 5D and 5E , NIH3T3-EN and Scg6-EN cells were negative by immunohistoforming oncoprotein not only in mesenchymal cells but also in breast epithelial cells. chemistry for cytokeratin or other epithelial markers, but were positive for the mesenchymal intermediate filament, vimentin ( Figures 5G and 5H) . In contrast, Eph4-EN derived tumors Discussion showed obvious gland formation and sheets of epithelioid cells ( Figure 5C ). Gland cells were strongly positive for cytokeratin
In this report we show that human secretory breast carcinoma is characterized by expression of the t(12;15)-associated ETV6-( Figure 5F ) and epithelial membrane antigen (data not shown) but negative for vimentin ( Figure 5I ). Adjacent to the epithelial NTRK3 gene fusion. Moreover, we demonstrate that the ETV6-NTRK3 chimeric product can transform normal mouse mamclusters were bands of vimentin-positive, cytokeratin-negative cells with a similar mesenchymal appearance as the Scg6-EN mary epithelial cells, strongly implicating this oncoprotein as being causally related to the development of SBC. SBC theretumors. There was an approximately equal contribution of the epithelial and mesenchymal neoplastic cells to the Eph4-EN fore joins a very select group of epithelial malignancies, namely subtypes of thyroid carcinomas (Pierotti, 2001), renal carcinotumors. Immunohistochemical staining of sections using ␣-NTRK3 antibodies demonstrated EN expression in the mas (Cooper and Shipley, 2002) , and aggressive sinonasal carcinoma (French et al., 2001) , for which recurrent gene fusions NIH3T3-EN and Scg6-EN cells ( Figure 5J and 5K), and in both the glandular and mesenchymal elements of the Eph4-EN dehave been described. ETV6-NTRK3 is unique among these gene fusions in that it is expressed in multiple tumor types including rived tumors ( Figure 5L ). These data show that EN-expressing those derived from mesenchymal (Knezevich et al., 1998a, promoter of a given chimeric gene is not active in a particular cell type, then the product of that gene will not be expressed. 1998b; Rubin et al., 1998), hematopoietic (Eguchi et al., 1999) , and now epithelial cells.
Similarly, if a chimeric oncoprotein is generally not tolerated in cells, e.g., if it induces apoptosis, then it will only be expressed The identification of an ETV6-NTRK3 gene fusion in SBC describes a recurrent chromosomal rearrangement and expresin cell types with mechanisms for circumventing oncogeneinduced apoptotic pathways. Evidence for the latter comes from sion of a dominantly acting oncogene as a primary event in breast carcinoma. The chromosomal instability observed in the recent studies of the Ewing tumor-associated EWS-FLI1 chimeric transcription factor. Expression in primary human fibroblasts vast majority of epithelial malignancies, leading to numerous rearrangements, gains, and losses of chromosomal material activated a p53-dependent growth arrest pathway and downregulated numerous cell cycle progression related genes (Less- (Dickson and Lippman, 2001) , has precluded the discovery of primary genetic events underlying the development of epithelial nick et al., 2002) . This suggests that cells transformed by EWS-FLI1 must coactivate pathways that specifically abrogate tumors. If expression of ETV6-NTRK3 is indeed a causal event in secretory breast carcinoma, then transformation of breast EWS-FLI1-induced growth arrest in order for mitogenesis to occur and for tumors to form. The second explanation for tumor epithelial cells by the EN oncoprotein may provide an extremely useful model to study pathways leading both to the initiation specificity of fusion genes proposes that the chimeric oncoprotein itself can induce differentiation, giving rise to the observed and progression of breast cancer. In fact, there are several parallels between the signaling alterations described for EN phenotype. Many gene fusions in hematopoietic malignancies and sarcomas encode chimeric transcription factors (Sorensen fibroblast transformation and those observed in breast cancer. We previously reported that EN is a potent transforming protein and Triche, 1996) . Therefore these proteins may transcriptionally activate specific differentiation programs. EWS-FLI1 expression in NIH3T3 cells and that this activity requires a functional NTRK3 PTK domain (Wai et al., 2000) . Moreover, EN transformation in NIH3T3 cells was associated with a small round cell morphology and limited neural differentiation in nude mouse tumors leads to marked induction of cyclin D1 and is dependent on two major effector pathways of wild-type NTRK3, the Ras-MAPK (Teitell et al., 1999) , and a myogenic transcription program was induced in NIH3T3 cells expressing the alveolar rhabdomyosarpathway and the PI3K-AKT pathway (Wai et al., 2000; Tognon et al., 2001 ). Amplification and overexpression of the cyclin D1 coma-associated PAX3-FKHR protein (Khan et al., 1999) . We favor the view that some chimeric oncoproteins such (CCND1) gene is a well-known progression-related alteration in breast cancer (Buckley et al., 1993; Wang et al., 1994; Sicinski as EN may activate transformation pathways that function independently of lineage constraints and do not directly affect differet al., 1995), being present in approximately one-third of invasive cases (Zukerberg et al., 1995) . Moreover, the Ras-MAPK and entiation programs. These oncoproteins may modulate common signal transduction cascades present in diverse cell types PI3K-AKT pathways are receiving increasing attention as potential therapeutic targets in breast cancer (reviewed in Malaney that potentiate downstream proliferative effects such as transit through the cell cycle. In such a scenario it may be the ability and Daly, 2001, and Mills et al., 2001, respectively) . Another pathway suspected to play a key growth regulatory role in breast of the cell to tolerate the potentially toxic consequences of fusion protein expression, such as by activating complementary cancer is the insulin-like growth factor 1 receptor (IGFRI) cascade (reviewed in Zhang and Yee, 2000) . Interestingly, we recell survival pathways, which determines whether or not tumor formation occurs. In this context, the observed morphology of cently found that expression of functional IGFRI is essential for EN-mediated transformation, as EN fails to transform IGFRI neoplastic cells results from developmental programs already present in tumor precursor cells. Therefore the perceived specinull fibroblasts (Morrison et al., 2002) . EN transformation may provide a unique model to study how these and other pathways ficity of gene fusions may be more a function of the available complement of secondary pathways or the tendency for recontribute to breast oncogenesis. It will also be important to determine whether activation of the NTRK receptor PTK family quired additional mutations to occur than of the intrinsic differentiation program available in the precursor cell. by alternative mechanisms is a more general phenomenon in human breast cancer. In fact, recent reports document NTRK Experimental procedures expression in malignant breast epithelial cells (Descamps et al., 1998 (Descamps et al., , 2001b (Descamps et al., , 2001a .
Patient information

Tumors derived from EN-expressing Eph4 cells showed epi-
The clinical features of the 13 SBC cases assessed in this study are listed thelial differentiation with cytokeratin-and EMA-positive gland in Table 1 . The cases were accrued from Pathology departments at four of formation. Therefore not only is EN capable of transforming the authors' institutions (Children's and Women's Health Centre of British Columbia, Hospital for Sick Children, Instituto de Patologia e Imunologia cells with epithelial developmental potential, but it does not Molecular da Universidade do Porto, and Gerhard-Domagk-Institute of Pablock epithelial differentiation, in keeping with the well-differentithology, Westfaelische-Wilhelms University) and from Burnaby General Hosated histology of human SBC. However, the fact that EN exprespital, Burnaby, Canada. The age range was 6 to 76 years, and there was sion is associated with tumors derived from multiple lineages a 12:1 female to male ratio. Assessment of the pathologic records and calls into question the concept that gene fusions are specific independent review of slides from each case confirmed the secretory compofor given tumor types (Rabbitts, 1994) . Two possible mechanent as being the predominant or exclusive morphology present in the tumors, other than in cases 3 and 7. In case 3 the secretory carcinoma componisms have been proposed to explain the strong association nent was present within a background of gynecomastia, while in case 7 the between acquired chromosomal translocations and specific tusecretory component was admixed approximately equally with non-SBC mor types that has been documented in hematopoietic maliginfiltrating ductal carcinoma. All blocks used for molecular analysis were nancies and sarcomas (Barr, 1998) . The first proposes that the screened for the presence of at least 50% viable tumor tissue. (Sandberg and Bridge, 1994) . The samples were mechanically and enzymatically disaggregated and cultured in RPMI Canada) and maintained in DMEM/F12 (Sigma) supplemented with 5% FBS (Hyclone), insulin (5 g/ml; Sigma), and gentamicin (50 g/ml, GIBCO-BRL). 1640 medium supplemented with 20% fetal calf serum, 1% penicillin/streptomycin, and 1% L-glutamine for several days. Six hours before harvesting, cells were exposed to Colcemid (0.02 g/ml). After a brief incubation in Generation of retrovirally transduced cell lines hypotonic solution, the preparations were fixed with methanol-glacial acetic Retroviral vector plasmid DNAs (MSCV-puromycin vector or MSCV puromyacid (3:1). Metaphase cells were banded with Wright stain or with Giemsa cin ETV6-NTRK3 [Wai et al., 2000] ) were transfected into the BOSC23 ecotrypsin. A minimum of 20 metaphases were analyzed for each specimen.
tropic retroviral packaging cell line using calcium phosphate precipitation Karyotypes were in accordance with the International System for Human as described (Pear et al., 1993) . Supplemental Gag/Pol (pGP1) and Env Cytogenetic Nomenclature (1995) .
plasmids were used during the transfection procedure to increase viral titres. Retrovirus-containing supernatants were collected 48 hr after transfection and used to infect NIH3T3, Scg6, and Eph4 cells. Infected cells were selected RT-PCR analysis of breast tumor specimens for using 1.5 g/ml puromyocin (Sigma) for 48 hr. Protein expression was Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determined by Western blotting as described (Wai et al., 2000) . screen for ETV6-NTRK3 fusion transcripts in frozen tissue samples from the index case and an additional 50 control cases of infiltrating ductal carcinoma Immunoprecipitation studies using previously described methods (Knezevich et al., 1998b) . Total RNA Lysates were prepared from scrolls of frozen tumor samples embedded in was used as starting material and was isolated using standard procedures.
OCT using a RIPA lysis buffer consisting of 20 mM Tris pH 7.4; 120 mM NaCl, The TEL541 forward primer (5Ј-CCTCCCACCATTGAACTGTT-3Ј) and the 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10% glycerol, 5 TRKC2 reverse primer (5Ј-CCGCACACTCCATAGAACTTGAC-3Ј) were used mM EDTA, 50 mM NaF, 0.5 mM Na 3 VO 4 , plus freshly added protease inhibifor PCR. Amplified products were visualized by electrophoresis using 2% tors (Leupeptin [10 g/ml], Apoprotinin [10 g/ml], and PMSF [250 M]). agarose gels stained with ethidium bromide. ETV6-NTRK3 amplification Lysates prepared from cell lines were prepared as described previously products were confirmed by blotting the PCR fragments onto Hybond-N (Tognon et al., 2001) . Protein quantification was performed using a DC nylon filters followed by hybridization with an oligonucleotide probe as deprotein assay kit (BioRad). Immunoprecipitation studies to detect ETV6-scribed (Bourgeois et al., 2000) , and by sequencing of the PCR products.
NTRK3 were performed on 500 g of total cell lysate (TCL) using 5 l of The presence of amplifiable RNA in all samples was confirmed by RT-PCR ␣-TrkC 14 antibodies (Santa Cruz) and 20 l of Protein A sepharose (Amerusing control primer sets.
sham Pharmacia Biotech). Washed immunoprecipitates were electropho-RT-PCR of ETV6-NTRK3 fusion transcripts in formalin-fixed paraffinresed using 10% SDS-polyacrylamide gels, and transferred to Immobilon-P embedded sections was based on previously described methods (Bourgeois (Millipore) PVDF prior to immunoblot analysis with 4G10 ␣-phosphotyrosine et al., 2000) . Briefly, RNA was isolated from three 30 m paraffin sections antibodies (Upstate). Proteins were visualized with ECL (Amersham) acand used directly in a one-step RT-PCR reaction using the Biosciences cording to the manufacturer's protocols. Blots were stripped and reprobed Titanium One Step RT-PCR kit (Clontech). First, the RNA was checked for with ␣-TrkC14 antibodies to verify the presence of ETV6-NTRK3. integrity using primer pairs for the phosphoglycerate kinase (PGK) gene, as described previously (Bourgeois et al., 2000) . The RNA was then subjected to RT-PCR using sense TEL971 (5Ј-ACCACATCATGGTCTCTCTGTCTCCCTumor growth in nude mice 3Ј) and antisense TRKC1059 (5Ј-CAGTTCTCGCTTCAGCACGATG-3Ј) primTwo million NIH3T3, Eph4, or Scg6 cells expressing either control MSCV ers (Bourgeois et al., 2000) . PCR conditions were as reported previously, vectors or ETV6-NTRK3 constructs were injected subcutaneously into the with the assay detecting a 110 bp PCR fragment. Products were confirmed left flanks (MSCV cell lines) or right flanks (ETV6-NTRK3 expressing cell as ETV6-NTRK3 transcripts by oligonucleotide probing as described above.
lines) of five nude male mice per cell line. Tumor injection sites were monitored three times weekly. Calliper measurements were taken when the tumors were large enough to assay. Tumors were excised and weighed after Fluorescence in situ hybridization (FISH) 20 days (for NIH3T3 cells) or 48 days (for Eph4 and Scg6 cell lines) and Two FISH assays were used to detect the t(12;15) translocation in SBC.
average tumor weights were calculated. Tumor growth over time was estiSlides containing interphase cell spreads of the index case were prepared mated using the following equation: tumor length ϫ tumor width ϫ tumor from frozen tumor tissue and subjected to dual-color FISH as previously height ϫ 0.5236. described (Knezevich et al., 1998b) . Probes used included ETV6 exon 1-containing cosmid 179A6 and ETV6 exon 8-containing cosmid 148B6, which become separated in cells with the t(12;15) translocation (Knezevich Tumor histology et al., 1998b) . For analysis of chromosome breakpoints in formalin-fixed Sections from excised tumors were fixed in 10% formalin and embedded paraffin-embedded tumor blocks, 5 m sections were first deparaffinized in paraffin using standard protocols. Sections were cut at 5 m and stained and dehydrated in 100% ethanol using standard methods. Slides were boiled with hematoxylin and eosin (H/E). Immunohistochemistry (IHC) was perin 2xSSC for 30 s, washed, and then pretreated in 1M sodium thiocyanate formed on formalin-fixed paraffin-embedded sections using a three-step for 30 min. Sections were then digested using 5 mg/ml pepsin in 0.2N HCL streptavidin-biotin peroxidase method, with 3-amino-9-ethylcarbazole as at 37ЊC for 20 min. This was followed by fixation in formaldehyde, dehydration the chromogen. Antibodies utilized included cytokeratin (Z0622 from Dako; with ethanol, and denaturation with 70% formamide/2xSSC (pH 7.0) at 90ЊC 1:1000 dilution), epithelial membrane antigen (EMA; ID Laboratories; 1:50), for 6 min. Dual-color FISH was performed using the 12p13 breakpointcarcinoembryonic antigen (CEA; Dako; 1:200), NTRK3 (TRKC14 from Santa spanning YAC, 817_H_1 and the 15q25 breakpoint-spanning YAC, 802_B_4
Cruz; 1:40), and vimentin (Nova Castro; 1:100). Microwave antigen retrieval (Knezevich et al., 1998b) . Probes were labeled with Spectrum Green was performed using standards methods. Photomicrographs were taken (817_H_1) and 0.2 Spectrum Red (802_B_4) by nick translation following with a Zeiss Axioplan 2 microscope equipped with Northern Eclipse version standard protocols, and hybridized to denatured slides in a humid chamber 5.0 software. at 37ЊC overnight. These probes become juxtaposed in cells with the t(12;15) translocation (Knezevich et al., 1998b) . Slides were counterstained with DAPI Acknowledgments and analyzed using a Zeiss Axioplan epifluorescent microscope equipped with a COHU-CCD camera.
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